GlassScriptPhysician profile
Emily Brill
NPI 1801572029
$943.22
in general payments reported to CMS, 2019-2025
11 companies · $753 in 2025
The $753 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $191 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $366.62 | 2024-2025 | Miebo, Xiidra |
| Mallinckrodt Hospital Products INC. | $170.29 | 2024-2025 | Acthar |
| Oyster Point Pharma, INC. | $75.31 | 2024-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $59.82 | 2025 | |
| Alcon Vision LLC | $59.46 | 2024-2025 | Tryptyr, Rocklatan |
| Dompe US, INC. | $53.44 | 2024-2025 | Oxervate |
| Biotissue Holdings INC. | $46.41 | 2025 | |
| Apellis Pharmaceuticals, INC. | $32.85 | 2025 | Syfovre |
| Genentech USA, INC. | $30.68 | 2025 | Susvimo |
| Harrow Eye, LLC | $30.05 | 2025 | Vevye |
| Astellas Pharma US INC | $18.29 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Brill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.